Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$2.40 -0.01 (-0.41%)
2/9/2010 4:00 PM

Array BioPharma, Inc. (ARRY)

CAPS Rating:
****

A biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ARRY

Add Stock to Watchlist

What the Community Thinks

Total Members

226 Outperforms
9 Underperforms
 

All-Stars

91 Outperforms
3 Underperforms
 

Wall Street

12 Outperforms
0 Underperforms
 

Members bullish on ARRY are also bullish on:

Members bearish on ARRY are also bearish on:

Ticker Tags

Healthcare (711), Micro Cap (4701), Rule Breakers Universe (125), Biotechnology (220), Research (13), Defensive (1457)
Suggest a tag

Array BioPharma, Inc. At A Glance

Current Price: $2.40
Last Trade Time: 2/9/2010 4:00 PM
Open: $2.44
Previous Close: $2.41
Daily Range: $2.35 - $2.44
52-Week Range: $1.68 - $4.65
Volume: 250,779
Market Cap: $121.38M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

ARRY VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Array BioPharma, Inc. (ARRY)

Avatar 21popsontop (66.97) Submitted: 1/28/10 10:21 AM

Has always had that longshot look, and now we see the big boys taking them out for dinner and paying for friendship, advise and technology expertise. Looks much better than DNDN for sure and even has real products on the market and several more in the oven. One to watch.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Array BioPharma, Inc. (ARRY)

Avatar cashsage (32.22) Submitted: 12/07/09 3:27 PM

ARRY has a too high valuation compared to its sales potential. It is also one of the most loss making companies. It may go bankrupt.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 23 :   1 2 3 4 5 Next »

Show Pitch Replies

Recs

1

 (ARRY)

Avatar 21popsontop (66.97) Submitted: 1/28/10 10:21 AM : Outperform Start Price: $2.51 ARRY Score: -2.57

Has always had that longshot look, and now we see the big boys taking them out for dinner and paying for friendship, advise and technology expertise. Looks much better than DNDN for sure and even has real products on the market and several more in the oven. One to watch.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ARRY)

Avatar PharmaInvestor (< 20) Submitted: 1/24/10 3:12 PM : Outperform Start Price: $2.49 ARRY Score: -0.83

Several shots on goal (7 to be precise) each with a compelling product profile. Financing environment - ARRY's achilies heel - is getting better.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (ARRY)

Avatar lola99999 (< 20) Submitted: 12/16/09 9:33 PM : Outperform Start Price: $2.57 ARRY Score: -3.45

ARRY

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (ARRY)

Avatar cashsage (32.22) Submitted: 12/07/09 3:27 PM : Underperform Start Price: $2.09 ARRY Score: -17.95

ARRY has a too high valuation compared to its sales potential. It is also one of the most loss making companies. It may go bankrupt.

Report this Post Replies: 0 | Reply | Permalink

Recs

2

 (ARRY)

Avatar redwings103149 (20.10) Submitted: 9/15/09 11:03 PM : Outperform Start Price: $2.84 ARRY Score: -17.03

What a great price to get into this stock. Well little history on arry was that they have had a hugeeee pipeline but have been blessed with some terrible along with a trial 3 data result that did not meet its ends. Away from the bad they have four game changers due within the next 6months so spec alone will hype this baby up eventually.

Report this Post Replies: 1 | Reply | Permalink

Results 1 - 5 of 23 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 12 of 12  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackUBS 87.99 11/10/09 Outperform NS $2.03+18.23%-0.68%+18.90
TrackWMBlair 69.55 02/07/08 Outperform NS $5.66-57.60%-15.72%-41.88
TrackMorganJos < 20 12/04/07 Outperform NS $11.40-78.95%-23.41%-55.54
TrackCollinsStew 68.03 11/07/07 Outperform NS $9.95-75.88%-25.33%-50.55
TrackLehmanBros 85.06 10/09/07 Outperform NS $10.90-77.98%-27.81%-50.17
TrackEveillard 93.31 09/30/07 Outperform NS $11.23-78.63%-26.38%-52.25 Toggle the visibility of 60-Second Pitch and replies
TrackRodmanRen < 20 08/13/07 Outperform NS $11.06-78.30%-22.96%-55.34
TrackJPMorgan 84.76 05/23/07 Outperform NS $13.01-81.55%-25.89%-55.66
TrackPiperJaff 85.79 01/04/07 Outperform NS $12.57-80.91%-19.42%-61.49
TrackOppenheimer 81.36 12/15/06 Outperform NS $13.02-81.57%-20.33%-61.24
TrackWRHambrecht 64.18 11/09/06 Outperform NS $11.92-79.87%-18.14%-61.72
TrackBofASec 94.61 11/02/06 Outperform NS $9.60-75.00%-17.26%-57.74

Results 1 - 12 of 12  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD01 875ms